Solomina A A, Grudinin M P, Eropkin M Iu, Karpova L S, Pisareva M M, Komissarov A B, Konovalova N I, Gudkova T M, Danilenko D M, Smorodintseva E A, Voĭtsekhovskaia E M, Kiselev O I
Zh Mikrobiol Epidemiol Immunobiol. 2011 May-Jun(3):20-6.
Characterization of features of influenza pandemic development in Russia in relation to global process.
Pandemic monitoring was performed by using results of integrative analysis of laboratory diagnostic and population morbidity data from 49 supporting bases of Federal center of influenza from various cities in Russian Federation. Isolation of influenza virus was carried out in MDCK cells and chicken embryos under BSL-3 conditions. Reference virus A/California/07/09 obtained from CDC (Atlanta, USA) and antisera against this strain contained in WHO kit were used for antigenic analysis; rat antisera, new monoclonal antibodies against pandemic influenza virus developed by Research institute of influenza were also used.
Based on PCR monitoring during epidemic peak, rate of pandemic influenza identification reached 45-49% of examined patients. About 53% of lethal cases of respiratory infections were caused by pandemic influenza virus, while predominately young people died from pneumonia and acute respiratory distress syndrome. Russian isolates generally were antigenically and genetically similar to the parent pandemic strain--influenza virusA/California/07/09, but contained S203T substitution in hemagglutinin. A number of strains contained D222G mutation that is responsible for the expansion of substrate specificity, as well as strain specific substitutions in hemagglutinin and neuraminidase molecules. The investigated isolates were resistant to remantadin, but sensitive to oseltamivir.
Due to the formation of population immunity after the end of the first pandemic wave new drift variants of the virus capable of overcoming this formed immunity should be expected that apparently will require the correction of vaccine composition for the 2011 - 2012 season.
描述俄罗斯流感大流行发展特征及其与全球进程的关系。
通过对俄罗斯联邦各城市49个联邦流感中心支持基地的实验室诊断结果和人群发病率数据进行综合分析来开展大流行监测。在生物安全3级条件下,于MDCK细胞和鸡胚中进行流感病毒分离。使用从美国疾病控制与预防中心(亚特兰大)获得的参考病毒A/加利福尼亚/07/09以及世界卫生组织试剂盒中含有的针对该毒株的抗血清进行抗原分析;还使用了大鼠抗血清、流感研究所研制的针对大流行性流感病毒的新型单克隆抗体。
基于流行高峰期间的PCR监测,大流行性流感的确诊率在受检患者中达到45% - 49%。约53%的呼吸道感染致死病例由大流行性流感病毒引起,而主要是年轻人死于肺炎和急性呼吸窘迫综合征。俄罗斯分离株在抗原性和基因上一般与大流行亲本毒株——流感病毒A/加利福尼亚/07/09相似,但血凝素中存在S203T替换。一些毒株含有导致底物特异性扩大的D222G突变,以及血凝素和神经氨酸酶分子中的毒株特异性替换。所研究的分离株对金刚烷胺耐药,但对奥司他韦敏感。
由于第一波大流行结束后人群免疫力的形成,预计会出现能够克服这种已形成免疫力的病毒新漂移变体,这显然将需要对2011 - 2012季节的疫苗成分进行调整。